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Late-onset hypogonadism (LOH) is an emerging 
pathophysiological entity. Not everybody is familiar with 
LOH or even recognizes its existence. Since the 19th century 
women’s life expectancy has become progressively greater 
than that of men and therefore their ailments associated with 
aging from the climacteric onwards  attracted medical attention 
much earlier than male aging health problems. In addition, 
male aging problems start at a later age than the climacteric 
occurs in women. However, men’s life expectancy is also 
continuously increasing: in Europe a newborn male now has a 
life expectancy of about 75 years, and a 60-year-old man has a 
statistical possibility of reaching 80 years of age. The increasing 
number of aging men forces physicians to focus on their health 
problems. 
Hypogonadism is defined as any impairment of testicular 
function, endocrine or exocrine, or both, resulting in lack of 
androgenicity and infertility. If the cause of hypogonadism 
resides in the testes themselves, it is characterized as primary; 
if causes lie in the hypothalamus or pituitary the term secondary 
hypogonadism is used (for review1). Cross sectional2 and 
longitudinal studies3 have shown that testosterone slowly 
declines with advancing age. Testosterone stays above the 
lower limit of normal in many aging men, but declines below 
that threshold in a percentage of men and this percentage 
increases progressively with advancing age.4 The Leydig cell 
reserve capacity for testosterone biosynthesis is impaired as 
evidenced by decreasing response to hCG stimulation, indicating 
a primary testicular element in causing these changes. At the 
same time, amplitude and order of LH pulses as well as the 
pituitary’s capacity to respond do GnRH stimulation of LH 
secretion are impaired, indicating a secondary element in the 
aging process of the hypothalamo-pituitary-testicular system. 
While spermatogenesis continues fertility can be maintained 
lifelong albeit at a reduced level.5 In conclusion, testicular 
function declining with progressing age is caused by impaired 
testicular as well as pituitary function. When in this process 
testosterone levels drop below the lower limit of normal it is 
justified to speak of late-onset hypogonadism (LOH) which 
has a combined pituitary and testicular aetiology. However, 
LOH is not only a biochemical diagnosis, clinical symptoms 
are at least equally important and prompt  the patient to ask 
for medical advice. 
Once the diagnosis of LOH has been established the 
therapeutic consequence would be testosterone substitution as 
in other forms of hypogonadism. While testosterone substitution 
in primary and secondary hypogonadism has belonged to the 
standard therapeutic repertoire for over 60 years, comparatively 
few studies to date have dealt with the benefits and risks of 
testosterone substitution in LOH. Especially, long-term studies 
on the effects of testosterone substitution in LOH are lacking and 
research is now focussed on the effects of testosterone in aging 
men. Nevertheless, some benefits e.g. for body composition, 
bones, metabolism, sexual functions and cognition are already 
know and further possible benefits e.g. for the cardiovascular 
system6 , in diabetes treatment7 and the metabolic syndrome8 
are emerging. Also implications for the prostate and lower 
urinary tract symptoms (LUTS) are under investigation. So 
far, the dogma prevails that testosterone should not be given 
to a patient with prostate carcinoma which has to be excluded 
before any testosterone treatment.
Although testosterone has been available for clinical use for 
over 60 years the treatment options for substitution therapy 
were rather limited until quite recently. New transdermal, 
buccal and injectable testosterone preparations, however, now 
result in the desired pharmacokinetic profile mimicking a serum 
testosterone and profiles of healthy younger men (for review9) 
and offer the possibility of treating LOH.
Testosterone treatment of LOH, however, should by 
no means be administered to aging men indiscriminately. 
Testosterone should be given to aging men only under strict 
criteria and under tight surveillance. In this regard, the 
International Society of Andrology (ISA) and the International 
Society for the Study of the Aging Male (ISSAM) set up a panel 
of experts which was later joined by the European Association of 
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Urology (EAU) to draft recommendations for the investigation, 
treatment and monitoring of LOH which are reprinted in this 
issue.10 These recommendations translate current scientific and 
clinical knowledge about LOH into practice. They provide the 
physician with guidelines for dealing with aging men suffering 
from LOH.
The question remains who should deal with LOH and 
patients afflicted by it? Unlike for women who have a medical 
speciality dealing with female reproductive and health problems 
throughout their life cycle, men often do not know whom to 
consult. Isn’t it about time that a medical (sub-) speciality 
deals specifically with male problems? There are now about 40 
learned societies around the globe dealing with “andrology”, 
but there are very few countries where andrology has reached 
professional status in the medical system. Germany is the first 
country in Europe recognising andrology as a sub-speciality  for 
endocrinologists, urologists and dermatologists and hopefully 
for the benefit of men, other countries will follow soon.
Andrology concentrates on five areas: infertility, 
hypogonadism, erectile dysfunction, male senescence (especially 
LOH) and male contraception. All these areas have made 
significant diagnostic and therapeutic progress in recent years 
so that the critical mass warranting a (sub-) speciality has 
accumulated. Establishing andrology as a medical discipline 
marks an important step towards gender equality in health 
care. 
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